Combining locoregional and systemic therapies in liver cancer: from strategy to survival

References

[1] Reig M,Forner A.BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update.J Hepatol2026;84:631-54

[2] Zhong BY,Guan JJ.Combination locoregional and systemic therapies in hepatocellular carcinoma.Lancet Gastroenterol Hepatol2025;10:369-86

[3] Li X,Li Y.Thermal ablation therapy for hepatocellular carcinoma: recurrence mechanisms and intervention strategies.Hepatoma Res2025;11:25

[4] Hall B,Dervishi M,Sutter C.Yttrium-90 combination therapies in hepatocellular carcinoma: current evidence and future directions.Hepatoma Res2026;12:20

[5] Yu Z,Wang C.A baseline-lymphocyte-subset nomogram for predicting severe immune-related adverse events in hepatocellular carcinoma patients receiving TACE plus immunotherapy.Hepatoma Res2025;11:29

[6] Li C,Bao H,Guo J.Synergistic era: practice and reflection on TACE combined with systemic therapy in hepatocellular carcinoma.Hepatoma Res2026;12:36

[7] Ma Y,Li C,Li G.Relationship between transarterial chemoembolization treatment frequency and prognosis in hepatocellular carcinoma patients.Hepatoma Res2026;12:43